# A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

> **NCT01300247** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01300247
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-01
- **Final completion:** 2015-12
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300247, "A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01300247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*